Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10363628 | 0.95 | CYP3A4 (0.34) | CYP3A4TSHRCA2 | |
| SCHEMBL5539638 | 0.93 | CA2 (0.37) | CYP3A4TSHRCA2 | |
| SCHEMBL5545751 | 0.93 | CA2 (0.37) | CYP3A4TSHRCA2 | |
| SCHEMBL5543518 | 0.93 | CA2 (0.37) | CYP3A4TSHRCA2 | |
| SCHEMBL5541681 | 0.93 | CA2 (0.37) | CYP3A4TSHRCA2 | |
| SCHEMBL5544442 | 0.93 | CA2 (0.37) | CYP3A4TSHRCA2 | |
| SCHEMBL5545727 | 0.93 | CA2 (0.37) | CYP3A4TSHRCA2 | |
| SCHEMBL5537675 | 0.93 | CA2 (0.37) | CYP3A4TSHRCA2 | |
| SCHEMBL5541773 | 0.93 | ALDH1A1 (0.32) | CYP3A4TSHR | |
| SCHEMBL7675150 | 0.91 | CYP3A4 (0.34) | CYP3A4TSHRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186738-B2 | Antibacterial oxalidinones | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| US-7157482-B2 | Antibacterial 1,3-oxazolidin-2-one derivatives | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-20060084810-A1 | Antibacterial 1,3-oxazolidin-2-one derivatives | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | US | disclosed |
| US-20060079695-A1 | antibiotics such as (5R)-3-[3-Fluoro-4-(3-methylisoxazol-5-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one, having effective activity against both grampositive and gramnegative pathogens | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | US | disclosed |
| EP-1603903-A1 | ANTIBACTERIAL OXALIDINONES | AstraZeneca AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| EP-1603904-A1 | ANTIBACTERIAL 1, 3- OXAZOLIDIN -2- ONE DERIVATIVES | AstraZeneca AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004083205-A1 | ANTIBACTERIAL 1, 3- OXAZOLIDIN -2- ONE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083206-A1 | ANTIBACTERIAL OXALIDINONES | ASTRAZENECA AB (SE) | 2004-09-30 | — | — | WO | disclosed |
| EP-0813525-B9 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LAB (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6686364-B2 | 4-HYDROXY-3-((3,5-DIFLUORO-6-(3 -DIMETHYLAMINOCARBONYLPHENOXY)-4-(2-METHOXY-4-CARBOXYPHENOXY) PYRIDIN-2-YL)OXY)BENZAMIDINE, FOR EXAMPLE; FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 2004-02-03 | — | — | US | disclosed |
| WO-1999021860-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| US-5889005-A | Benzamidine derivatives and their use for treating thrombotic diseases | BERLEX LABORATORIES, INC. (US) | 1999-03-30 | — | — | US | disclosed |
| US-5883100-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5877181-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0813525-A1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5691364-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1997-11-25 | — | — | US | disclosed |
| WO-1996028427-A1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
| EP-0501167-B1 | Liquid dye preparations | BASF AG (DE) | 1995-07-05 | — | — | EP | disclosed |
| US-5205838-A | LIQUID DYE PREPARATIONS: BIS PHENYL-AZO-RESORCINOL IN SOLVENT FOR COLORED RIBBON OR BALL PEN INK | BASF AKTIENGESELLSCHAFT (DE) | 1993-04-27 | — | — | US | disclosed |
| EP-0501167-A1 | Liquid dye preparations | BASF Aktiengesellschaft (DE) | 1992-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084810-A1 | Antibacterial 1,3-oxazolidin-2-one derivatives | HRH1, HDHD5, NGLY1 | CYP3A4 337/4885TSHR 289/4885CA2 3151/4885 |
| US-20060079695-A1 | antibiotics such as (5R)-3-[3-Fluoro-4-(3-methylisoxazol-5-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one, having effective activity against both grampositive and gramnegative pathogens | HRH1, HRH2, HDHD5 | CYP3A4 1221/4885TSHR 83/4885CA2 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.